- Home
- SPNS vs JANX Comparison
SPNS vs JANX Comparison
Compare SPNS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNS
- JANX
- Stock Information
- Founded
- SPNS 1982
- JANX 2017
- Country
- SPNS Israel
- JANX United States
- Employees
- SPNS N/A
- JANX N/A
- Industry
- SPNS Computer Software: Prepackaged Software
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- SPNS Technology
- JANX Health Care
- Exchange
- SPNS Nasdaq
- JANX Nasdaq
- Market Cap
- SPNS 1.6B
- JANX 1.4B
- IPO Year
- SPNS 1992
- JANX 2021
- Fundamental
- Price
- SPNS $43.05
- JANX $23.41
- Analyst Decision
- SPNS Hold
- JANX Strong Buy
- Analyst Count
- SPNS 3
- JANX 10
- Target Price
- SPNS $31.33
- JANX $79.50
- AVG Volume (30 Days)
- SPNS 802.0K
- JANX 613.3K
- Earning Date
- SPNS 11-10-2025
- JANX 11-05-2025
- Dividend Yield
- SPNS 1.40%
- JANX N/A
- EPS Growth
- SPNS N/A
- JANX N/A
- EPS
- SPNS 1.22
- JANX N/A
- Revenue
- SPNS $549,037,000.00
- JANX $439,000.00
- Revenue This Year
- SPNS $8.50
- JANX N/A
- Revenue Next Year
- SPNS $6.83
- JANX $130.50
- P/E Ratio
- SPNS $35.24
- JANX N/A
- Revenue Growth
- SPNS 3.08
- JANX N/A
- 52 Week Low
- SPNS $23.69
- JANX $21.97
- 52 Week High
- SPNS $43.13
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- SPNS 84.24
- JANX 45.82
- Support Level
- SPNS $42.84
- JANX $23.62
- Resistance Level
- SPNS $43.09
- JANX $25.35
- Average True Range (ATR)
- SPNS 0.11
- JANX 1.13
- MACD
- SPNS -0.49
- JANX 0.04
- Stochastic Oscillator
- SPNS 75.76
- JANX 31.45
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.